ArticleAlzheimer's & dementia (New York, N. Y.)
Decentralizing dementia research to the US-Mexico border: the Rio Grande Valley AD-RCMAR as a model for translational equity.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The BEYONDD Pilot Study: A Decentralized Community-Engaged Research Framework for Multimodal Characterization of Neurodegenerative Risk in a Multi-Ethnic, Midlife Cohort with Subjective Cognitive or Behavioral Complaints.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Translational equity means ensuring that diagnostics, treatments, care models, and prevention strategies are developed and implemented so they work for populations with the greatest burden and least access to care. In Alzheimer's disease and related dementias (ADRD), where most evidence derives from highly educated, non-Hispanic White participants at large academic centers, translational equity is critical to prevent misclassification, limited access, and widening disparities and to ensure that underrepresented communities shape how new knowledge moves into practice. Hispanic and other populations in the United States are disproportionately affected by ADRD yet remain underrepresented in research, with gaps especially pronounced in high-poverty border regions such as the Rio Grande Valley (RGV) of South Texas. We describe the design and early outcomes of the Rio Grande Valley Alzheimer's Disease Resource Center for Minority Aging Research (RGV AD-RCMAR), a National Institute on Aging-funded P30 center located at a new, R2, Hispanic-Serving Institution. Drawing on program documents, center evaluation data, and alignment with national RCMAR statistics, we examine how the RGV AD-RCMAR's three cores, the Leadership and Administrative Core, Analysis Core, and Community Liaison and Recruitment Core (CLRC), and the Research Education Component (REC) were structured to decentralize where dementia research questions are generated, who leads that work, and how benefits flow back to the community. During the 2018 to 2023 cycle, the RGV center supported 14 early-career investigators, representing ∼5% of all scientists in the national RCMAR/AD-RCMAR portfolio and ∼12% of all AD-RCMAR scientists. The REC maintained 50% female representation, retained 70% of scholars at the institution after pilot funding, and saw scholars secure National Institutes of Health (NIH) K- and R-level awards. The CLRC has built a registry of over 600 residents interested in participation and documented hundreds of engagement activities and community changes, positioning the RGV AD-RCMAR as a border-based model for translational equity in AD/ADRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.